Plaque psoriasis: SKYRIZI (risankizumab) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.1
Psoriatic arthritis: SKYRIZI alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs.1
Podcast
November: Episode 5 Watch time: 20 min
Are all IL-23s the same?
The fifth episode explores how differences within the IL-23 inhibitor class may affect efficacy, safety and dosing outcomes for patients with moderate to severe psoriasis, with a focus on IL-23p19 inhibitors, including SKYRIZI® (risankizumab).
Podcast Series Host
Dr Laura Savage
Consultant Dermatologist at Leeds Centre for Dermatology, Chapel Allerton Hospital (Leeds Teaching Hospitals NHS Trust) and an Honorary Senior Lecturer at University of Leeds
Podcast Guest Speakers
Dr Shirin Zaheri
Imperial Healthcare NHS Trust and Imperial College London
Professor Kave Shams
University of Leeds and Leeds Centre for Dermatology
Podcasts:
References
- SKYRIZI (risankizumab) Summary of Product Characteristics.
UK-RISN-210517 Date of Preparation: October 2021
